[1] Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first-or second-line therapy in patients with metastatic renal cell cancer[J]. Journal of Clinical Oncology, 2007, 25(22):3288-3295. [2] Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B[J]. New England Journal of Medicine, 2004, 351(12):1206-1217. [3] Liu YJ. IPC:professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors[J]. Annu Rev Immunol, 2005, 23:275-306. [4] Vilcek J. Novel interferons[J]. Nature Immunology, 2003, 4(1):8-9. [5] Fensterl V, Sen GC. Interferons and viral infections[J]. Biofactors, 2009, 35(1):14-20. [6] De Veer MJ, Holko M, Frevel M, et al. Functional classification of interferon-stimulated genes identified using microarrays[J]. Journal of Leukocyte Biology, 2001, 69(6):912-920. [7] Foster GR, Finter NB. Are all type I human interferons equivalent?[J]. Journal of Viral Hepatitis, 1998, 5(3):143-152. [8] Mogensen KE, Lewerenz M, Reboul J, et al. The type I interferon receptor:structure, function, and evolution of a family business[J]. Journal of Interferon & Cytokine Research, 1999, 19(10):1069-1098. [9]Bell SJ, Fam CM, Chlipala EA, et al. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-α protein therapeutic[J]. Bioconjugate Chemistry, 2007, 19(1):299-305. [10]Jo YW, Youn YS, Lee SH, et al. Long-acting interferon-α 2a modified with a trimer-structured polyethylene glycol:Preparation, in vitro bioactivity, in vivo stability and pharmacokinetics[J]. International Journal of Pharmaceutics, 2006, 309(1):87-93. [11]Zhao HL, Yao XQ, Xue C, et al. Increasing the homogeneity, stability and activity of human serum albumin and interferon-α2b fusion protein by linker engineering[J]. Protein Expression and Purification, 2008, 61(1):73-77. [12]王磊, 何剑, 肖卫华.人干扰素α2b和IgG Fc片段融合蛋白显著延长体内半衰期[J].生物工程学报, 2008, 24(1):53-62. [13]Ceaglio N, Etcheverrigaray M, Kratje R, et al. Novel long-lasting interferon alpha derivatives designed by glycoengineering[J]. Biochimie, 2008, 90(3):437-449. [14] Ke Y, Huang WQ, Li J, et al. Enzymatic characteristics of a recom-binant neutral protease I(rNpI)from Aspergillus oryzae expressed in Pichia pastoris[J]. Journal of Agricultural and Food Chemistry, 2012, 60(49):12164-12169. [15]Sinclair G, Choy FYM. Synonymous codon usage bias and the expression of human glucocerebrosidase in the methylotrophic yeast Pichia pastoris[J]. Protein Expression and Purification, 2002, 26(1):96-105. [16] 奥斯伯FM, 金斯顿RE, 赛德曼JG. 精编分子生物学实验指南[M].颜子颖, 王海林, 译.北京:科学出版社, 1999. [17] 杨云霞, 朱玲, 王伯瑶, 等.人抗菌肽LL-37突变分子的特性和抗菌能力的比较[J].华西药学杂志, 2006, 21(5):422-424. [18]Kanthawong S, Bolscher JGM, Veerman ECI, et al. Antimicrobial and antibiofilm activity of LL-37 and its truncated variants against Burkholderia pseudomallei[J]. International Journal of Antimic-robial Agents, 2012, 39(1):39-44. [19]Fioravanti J, Medina-Echeverz J, Ardaiz N, et al. The fusion protein of IFN-α and apolipoprotein AI crosses the blood-brain barrier by a saturable transport mechanism[J]. The Journal of Immunology, 2012, 188(8):3988-3992. [20]Tian S, Li Q, Yao W, et al. Construction and characterization of a potent, long-lasting recombinant human serum albumin-interferon α1 fusion protein expressed in Pichia pastoris[J]. Protein Expression and Purification, 2013, 90(2):124-128. [21]Hemmerle T, Neri D. The dose dependent tumor targeting of antibody-interferon gamma fusion proteins reveals an unexpected receptor trapping mechanism in vivo[J]. Cancer Immunology Research, 2014:canimm. 0182.2013. [22]Wang D, Ren H, Xu JW, et al. Expression, purification and characterization of human interferon-γ in Pichia pastoris[J]. Molecular Medicine Reports, 2014, 9(2):715-719. [23]Cheung RCF, Wong JH, Ng TB. Immobilized metal ion affinity chromatography:a review on its applications[J]. Applied Microbiology and Biotechnology, 2012, 96(6):1411-1420. [24]Wu D, Chu J, Hao YY, et al. High efficient production of recombinant human consensus interferon mutant in high cell density culture of Pichia pastoris using two phases methanol control[J]. Process Biochemistry, 2011, 46(8):1663-1669. |